LONDON/TAIPEI – AstraZeneca’s COVID-19 vaccine performed better than expected in a major late-stage trial, paving the way for its potential emergency authorization in the United States and boosting confidence in the shot after setbacks in Europe.
The drugmaker said on Monday that interim data from trials in Chile, Peru and the United States found the vaccine was 79% effective in preventing symptomatic COVID-19 and, crucially, posed no increased risk of blood clots.
AstraZeneca intends to request U.S. emergency authorization for the vaccine, which was developed in conjunction with Oxford University, in the coming weeks.
In Japan, AstraZeneca filed for approval of the vaccine in early February. The Japanese government in December signed a contract to procure 120 million doses of the AstraZeneca shot, enough for 60 million people.
More than a dozen European countries, including Germany and France, halted use of the vaccine earlier this month after reports linked it to a rare blood clotting disorder in a very small number of people.
KEYWORDS
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.